CervoMed Stock (NASDAQ:CRVO)

Forecast Revenue Ownership Financials Chart

Previous Close

$10.41

52W Range

$5.85 - $26.38

50D Avg

$13.81

200D Avg

$17.15

Market Cap

$83.20M

Avg Vol (3M)

$80.59K

Beta

-

Div Yield

-

CRVO Company Profile

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

May 23, 2008

Website

CRVO Performance

CRVO Financial Summary

	Dec 23	Dec 22	Dec 21
Revenue	$7.14M	-	-
Operating Income	$-7.81M	$-3.48M	$-16.04M
Net Income	$-2.17M	$-5.80M	$-24.10M
EBITDA	$-7.81M	$-3.48M	$-15.94M
Basic EPS	$-0.82	$-11.20	$-18.51
Diluted EPS	$-0.82	$-11.20	$-18.51

Fiscal year ends in Dec 23 | Currency in USD